The overall goal of this proposal is to develop an understanding of the interaction of complement-receptor expressing cells with either complement-treated HIV-infected cells or complement-treated HIV. After infection with HIV, cells express viral proteins on their surface which can lead to cell-surface deposition of complement breakdown products. Since many immune effector cells express receptors for-these complement breakdown products, the complement activation by infected cells could potentially have a great impact on infected cell survival or function. Cells that express complement receptors may also interact differently with HIV after it is exposed to complement; HIV can also potentially activate complement in vivo. The recent discovery that some CD4+ cells express complement receptors (CR2) suggests that this subset could be infected more easily by virus that bears complement-breakdown products on its surface. To address these problems, we specifically propose to; 1. Determine the ability of HIV-infected cells to activate complement. The complement pathway(s) by which complement is activated and requirements for cell type, virus strain and specific antibody will be assessed. Flow cytometric methods will be used. 2. Study the result of complement activation by HIV-infected cells on their destruction by complement-receptor positive effector cells. Macrophages, NK cells, and cells which mediate ADCC will be evaluated for complement-enhanced killing of infected targets. 51Cr-release, trypan blue and propidium iodide cytotoxic assays will be used to assess killing. 3.Determine the effect of complement activation by HIV on tropism for complement receptor positive cells. We will focus on the interaction of HIV with the recently described CR2+CD4+ subset of lymphocytes. Flow cytometric sorting and in vitro infection of uninfected cells will be performed. Possible in vivo infection of these cells will be assessed by obtaining them from infected persons and flow cytometrically analyzing and sorting to obtain subsets followed by HIV provirus DNA quatitation. The studies proposed here will help gain knowledge of the interaction between complement and HIV. An understanding of this interaction may enable the design of drugs or vaccine strategies which will bolster or supplement the ability of oomplement to benefit the infected person while avoiding any harmful effects.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI029661-02
Application #
3144544
Study Section
AIDS and Related Research Study Section 1 (ARRA)
Project Start
1992-02-01
Project End
1996-01-31
Budget Start
1993-02-01
Budget End
1994-01-31
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Rush University Medical Center
Department
Type
DUNS #
City
Chicago
State
IL
Country
United States
Zip Code
60612
Saarloos, M N; Sullivan, B L; Czerniewski, M A et al. (1997) Detection of HLA-DR associated with monocytotropic, primary, and plasma isolates of human immunodeficiency virus type 1. J Virol 71:1640-3
Saifuddin, M; Hedayati, T; Atkinson, J P et al. (1997) Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J Gen Virol 78 ( Pt 8):1907-11
Saarloos, M N; Koenig, R E; Spear, G T (1995) Elevated levels of iC3b and C4d, but not Bb, complement fragments from plasma of persons infected with human T cell leukemia virus (HTLV) with HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis 172:1095-7
Saifuddin, M; Landay, A L; Ghassemi, M et al. (1995) HTLV-I activates complement leading to increased binding to complement receptor-positive cells. AIDS Res Hum Retroviruses 11:1115-22
Saarloos, M N; Lint, T F; Spear, G T (1995) Efficacy of HIV-specific and 'antibody-independent' mechanisms for complement activation by HIV-infected cells. Clin Exp Immunol 99:189-95
Saifuddin, M; Parker, C J; Peeples, M E et al. (1995) Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med 182:501-9
Spear, G T; Lurain, N S; Parker, C J et al. (1995) Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J Immunol 155:4376-81
Munson, L G; Scott, M E; Landay, A L et al. (1995) Decreased levels of complement receptor 1 (CD35) on B lymphocytes in persons with HIV infection. Clin Immunol Immunopathol 75:20-5
Spear, G T; Ghassemi, M; Takefman, D M (1994) HIV-1 strain dependence of complement-mediated virolysis induced by recombinant CD4-IgG. J Acquir Immune Defic Syndr 7:100-1
Spear, G T; Takefman, D M; Sharpe, S et al. (1994) Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization. Virology 204:609-15

Showing the most recent 10 out of 13 publications